 |
|
|
| |
Bemnifosbuvir and Ruzasvir Provided as a Fixed-Dose Combination Demonstrates High Relative Bioavailability to Their Individual Formulations and Can Be Dosed With No Regard to Food
|
| |
| |
AASLD 2025 Nov 7-11 Wash DC
Xiao-Jian Zhou1, Brett Smith2, Maureen Montrond1, Keith Pietropaolo1, Bruce Belanger1, Shannan Lynch1, Dayle James1, Arantxa Horga1, and Janet Hammond1
1. Atea Pharmaceuticals, Inc., Boston, MA; 2. Altasciences, Los Angeles, CA
|
| |
|
|
|
|
|
